An investigational gene therapy has delivered the most convincing clinical evidence yet that a one-time treatment can slow the relentless course of Huntington’s disease, with patients in a Phase I/II trial showing a 75% reduction in disease progression at 36 months.
The pivotal study, conducted by gene therapy company uniQure, found that high-dose AMT-130 met its primary endpoint on the composite Unified Huntington’s Disease Rating Scale and also slowed functional decline by 60% on Total Functional Capacity (TFC), a clinical rating scale used to measure a person’s ability to function independently in daily life. It is part of the Unified Huntington’s Disease Rating Scale (UHDRS) and is one of the most widely used tools to stage disease progression.
The results, though yet to be peer-reviewed or published, have been recognised by experts as unprecedented and potentially transformative.



